<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126814</url>
  </required_header>
  <id_info>
    <org_study_id>04-0147-C</org_study_id>
    <nct_id>NCT01126814</nct_id>
  </id_info>
  <brief_title>A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I-II Study Evaluating the Safety and Efficacy of Imatinib Mesylate (Gleevec) Combined With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I-II study evaluating the toxicity and efficacy of imatinib combined with&#xD;
      mitoxantrone, etoposide and high-dose cytarabine reinduction therapy in relapsed and&#xD;
      refractory AML. Patients will be treated initially at a 200 mg dose of imatinib; if&#xD;
      tolerated, the imatinib dose will be escalated in subsequent cohorts to 300 mg and 400 mg.&#xD;
      Once the recommended dose is determined, the remaining patients will be treated at that dose,&#xD;
      to evaluate the antileukemic activity of the regimen. Patients achieving complete remission&#xD;
      will receive consolidation therapy with imatinib combined with high-dose cytarabine and&#xD;
      mitoxantrone, followed by maintenance imatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction therapy:&#xD;
&#xD;
        -  Imatinib 200-400 mg p.o. daily x 10 days, Days 1-10 (see dose escalation scheme in&#xD;
           Section 5.4 below).&#xD;
&#xD;
        -  Mitoxantrone 10 mg/m2 daily x 5 days, Days 4-8.&#xD;
&#xD;
        -  Etoposide 100 mg/m2 daily x 5 days, Days 4-8.&#xD;
&#xD;
        -  Cytarabine 1.5 grams/m2 q12h x 4 doses, Days 9-10 (for patients aged 60 years and over,&#xD;
           1.0 gram/m2).&#xD;
&#xD;
      Only one induction course will be permitted. Only patients achieving CR will proceed to&#xD;
      consolidation and maintenance.&#xD;
&#xD;
      Consolidation therapy, maximum 2 cycles (for patients achieving CR):&#xD;
&#xD;
        -  Imatinib 200-400 mg p.o. daily x 8 days, Days 1-8 (see dose escalation scheme in Section&#xD;
           5.4 below).&#xD;
&#xD;
        -  Mitoxantrone 12 mg/m2 daily x 2 days, Days 4-5.&#xD;
&#xD;
        -  Cytarabine 3 grams/m2 q12h x 6 doses, Days 4,6,8. For patients aged 60 years and over,&#xD;
           the dose will be reduced to 1.5 grams/m2.&#xD;
&#xD;
      Maintenance therapy (for patients still in CR at end of consolidation):&#xD;
&#xD;
      Imatinib 600 mg p.o. daily, until relapse or toxicity (see dose modification criteria in&#xD;
      Section 5.6.6 below). Patients must receive at least one consolidation cycle before being&#xD;
      permitted to proceed to maintenance therapy (see Section 5.6 for details). Maintenance&#xD;
      therapy with imatinib will be provided for a maximum period of 1 year.&#xD;
&#xD;
      Dose escalation scheme:&#xD;
&#xD;
      Imatinib will be used during induction and consolidation at one of the following dose levels:&#xD;
&#xD;
      Level -1 100 mg daily Level 1 200 mg daily Level 2 300 mg daily Level 3 400 mg daily&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity (hematologic and non-hematologic) of the combination of Imatinib and Chemotherapy consisting of Mitoxantrone, Etoposide and Ara-c</measure>
    <time_frame>2 years</time_frame>
    <description>Hematologic toxicity&#xD;
Number of days to ANC &gt; 0.5 and 1.0.&#xD;
Number of days until platelets &gt; 20 and &gt; 50, independent of platelet transfusions.&#xD;
Number of days until RBC transfusion independent. Non-hematologic toxicity, as per NCI common toxicity criteria Hematologic dose-limiting toxicity (DLT) defined as &gt; 40 days to ANC &gt; 0.5 or platelets &gt; 20 independent of transfusions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate - CR, MLFS and PR as per section 7.1</measure>
    <time_frame>2 years</time_frame>
    <description>Complete response&#xD;
Morphologic leukemia-free state&#xD;
Partial remission (PRâ€¢No response (NR): Does not meet the criteria for CR, MLFS or PR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of Imatinib when given in combination with chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum tolerated dose (MTD) of Imatinib (200, 300, 400 mg) when used in combination with NOVE-HiDAC induction and consolidation. MTD defined as highest dose resulting in up to 2/6 grade III-IV hematologic (as defined above) or non-hematologic DLTs per dose level. Non-hematologic DLTs as defined by NCIC CTC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of imatinib maintenance therapy.</measure>
    <time_frame>2 years</time_frame>
    <description>Hematologic&#xD;
Number of days to ANC &gt; 0.5 and 1.0.&#xD;
Number of days until platelets &gt; 20 and &gt; 50, independent of platelet transfusions.&#xD;
Number of days until RBC transfusion independent. Non-hematologic toxicity, as per NCI common toxicity criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity of imatinib maintenance therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission-free survival and overall survival.</measure>
    <time_frame>2 years</time_frame>
    <description>Median duration of remission free survival. Median overall survival and 2 year overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and phosphorylated c-kit activity at Days 1 and 4.</measure>
    <time_frame>2 years</time_frame>
    <description>levels of total and phosphorylated c-kit - pre and post imatinib/Gleevec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of downstream components of c-kit pathway at Days 1 &amp; 4.</measure>
    <time_frame>2 years</time_frame>
    <description>levels of phosphorylation ERK and AKT - pre and post imatinib/Gleevec</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>one</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib (Gleevec)</intervention_name>
    <arm_group_label>one</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AML, all subtypes except APL.&#xD;
&#xD;
          -  Prior induction therapy consisting of cytarabine 100-200 mg/m2 plus an anthracycline.&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  persistent leukemia after induction therapy.&#xD;
&#xD;
               -  relapse within two years of achieving complete remission with induction therapy.&#xD;
                  Any consolidation therapy is acceptable, including stem cell transplantation.&#xD;
&#xD;
          -  At least 10% bone marrow blasts, or biopsy confirmed extramedullary disease.&#xD;
&#xD;
          -  Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry.&#xD;
&#xD;
          -  Aged 18-65.&#xD;
&#xD;
          -  ECOG performance status &lt; 3 (see Appendix I).&#xD;
&#xD;
          -  No chemotherapy within the previous four weeks, other than hydroxyurea to control&#xD;
             counts. If hydroxyurea is used, it must be stopped at least 24 hours prior to starting&#xD;
             imatinib.&#xD;
&#xD;
          -  Able to given informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Active CNS leukemia.&#xD;
&#xD;
          -  Serum creatinine &gt; 200 umol/L.&#xD;
&#xD;
          -  Serum bilirubin &gt; 1.5 x ULN, AST or ALT &gt; 2x ULN.&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gleevec</keyword>
  <keyword>c-kit</keyword>
  <keyword>aml</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

